

## SUPPLEMENTARY DATA

**Table 1 of the supplementary data**

Baseline and Procedural Characteristics and In-hospital Outcomes According to Elevated Galectin-3

	Elevated Galectin-3 ( $\geq 8.71$ ng/mL)		<i>P</i>
	No (n = 299)	Yes (n = 140)	
Age, y	81.0 [77.0-84.5]	81.0 [77.0-85.0]	.928
Female sex	133 (44.5)	66 (47.1)	.675
BMI, kg/m <sup>2</sup>	25.7 [23.6-28.7]	26.2 [23.3-30.8]	.290
Logistic EuroSCORE I, %	13.9 [7.9-19.5]	14.7 [9.5-24.6]	.016
NYHA class III/IV	174 (58.2)	100 (71.4)	.010
Hypertension	270 (90.3)	128 (91.4)	.840
Hypercholesterolemia	232 (77.6)	116 (82.9)	.253
Diabetes mellitus	70 (23.4)	45 (32.1)	.068
Coronary artery disease	220 (73.6)	104 (74.3)	.968
Previous myocardial infarction	26 (8.7)	17 (12.1)	.337
Previous PCI	131 (43.8)	67 (47.9)	.490
Previous CABG	35 (11.7)	14 (10.0)	.714
Previous stroke	28 (9.4)	24 (17.1)	.028
Previous cancer	59 (19.7)	32 (22.9)	.531
Previous pacemaker	35 (11.7)	20 (14.3)	.544
Peripheral artery disease	40 (13.4)	19 (13.6)	1.000
COPD	39 (13.0)	32 (22.9)	.014
Atrial fibrillation	117 (39.1)	65 (46.4)	.179
Hemoglobin, g/dL	12.8 [11.6-13.9]	12.6 [11.1-13.7]	.168
Creatinine clearance, mL/min	56.0 [43.0-68.5]	49.0 [35.8-62.2]	.001
CRP, mg/L	1.9 [1.0-5.2]	3.0 [1.1-7.8]	.015
NTproBNP, ng/L	1500 [602-3575]	2520 [769-4770]	.020
CA125, U/mL	18.1 [10.8-38.0]	21.7 [13.0-40.8]	.066
Galectin-3, ng/mL	6.0 [4.6-7.3]	10.4 [9.3-14.5]	< .001
LV ejection fraction $\leq 35\%$	23 (7.7)	18 (12.9)	.119
Mitral regurgitation grade III/IV	11 (3.7)	12 (8.6)	.056
PAP > 60 mmHg	32 (10.7)	23 (16.4)	.125
Mean transaortic gradient, mmHg	45.0 [37.5-53.0]	41.0 [30.0-51.0]	.003
Device success	261 (87.3)	126 (90.0)	.509
Procedural success	291 (97.3)	139 (99.3)	.283
Procedural time, min	49.0 [40.5-57.0]	49.5 [40.0-61.0]	.399
Fluoroscopy time, min	11.4 [8.5-14.2]	11.6 [9.2-16.2]	.068
Contrast, mL	110.0 [90.0-140.0]	120.0 [100.0-140.0]	.109
Major vascular complication	43 (14.4)	21 (15.0)	.979
Life-threatening bleeding	9 (3.0)	8 (5.7)	.270
Blood transfusion, $\geq 2$ units	36 (12.0)	17 (12.1)	1.000
Major stroke	1 (0.3)	4 (2.9)	.038
Renal failure	2 (0.7)	8 (5.7)	.002
New pacemaker implantation	17 (5.7)	8 (5.7)	1.000
Days in hospital	4.0 [4.0-6.0]	5.0 [4.0-6.0]	< .001
Days in intensive care unit	1.0 [1.0-1.0]	1.0 [1.0-2.0]	< .001

BMI, body mass index; CA125, carbohydrate antigen 125; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; NTproBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; PAP, pulmonary artery pressure; PCI, percutaneous coronary intervention.

The data are expressed as No. (%) or median [interquartile range].

**Table 2 of the supplementary data**

## Incremental Prognostic Value of Gal3+ to Baseline Variables and CA125 and Within CA125 Stratae

	AUC		Reclassification	
	Base model*	Base model <sup>a</sup> + Gal3+	NRI [95%CI]	IDI [95%CI]
All (n = 439) <sup>b</sup>	.745	.748	38.4 (-17.6, 65.4)	1.0 (-0.3, 4.1)
CA125+ (n = 228)	.687	.712	49.2 (5.1, 77.8)	2.5 (-0.3, 8.6)
CA125- (n = 211)	.438	.411	-84.2 (-76.1, 76.7)	-0.4 (-1.6, 4.6)

95%CI, 95% confidence interval; AUC, area under the curve; CA125, carbohydrate antigen 125; EuroSCORE, European System for Cardiac Operative Risk Evaluation; NRI, net reclassification improvement, IDI, integrated discrimination improvement

<sup>a</sup>Including age, logistic EuroSCORE I, previous myocardial infarction, previous malignancy, atrial fibrillation, mitral regurgitation grade III/IV, pulmonary hypertension (PAP > 60 mmHg), hemoglobin (g/dL), creatinine clearance (mL/min), N-terminal pro-B-type natriuretic peptide (ng/L), Mean transaortic gradient (mmHg).

<sup>b</sup>Base model + CA125+

**Figure 1 of the supplementary data.** Kaplan-Meier event rate according to CA125. Kaplan-Meier estimates for the primary endpoint with differences tested using the log rank test. +, elevated, -, not elevated.

